The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 29, 2016

Filed:

Dec. 07, 2011
Applicants:

Kapil Dhingra, Sparta, NJ (US);

Brian Higgins, Fresh Meadows, NY (US);

Kenneth Kolinsky, Bloomingdale, NJ (US);

Richard J. Lee, New York, NY (US);

Brian Lestini, Union City, NJ (US);

Kathryn Packman, Bloomfield, NJ (US);

Fei Su, Paramus, NJ (US);

Inventors:

Kapil Dhingra, Sparta, NJ (US);

Brian Higgins, Fresh Meadows, NY (US);

Kenneth Kolinsky, Bloomingdale, NJ (US);

Richard J. Lee, New York, NY (US);

Brian Lestini, Union City, NJ (US);

Kathryn Packman, Bloomfield, NJ (US);

Fei Su, Paramus, NJ (US);

Assignee:

Hoffman La-Roche Inc., Nutley, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/535 (2006.01); A61K 31/505 (2006.01); A61K 38/21 (2006.01); A01N 43/54 (2006.01); A01N 43/42 (2006.01); C07D 413/00 (2006.01); C07D 239/02 (2006.01); C07D 401/00 (2006.01); C07D 403/00 (2006.01); C07D 471/02 (2006.01); A61K 31/437 (2006.01);
U.S. Cl.
CPC ...
A61K 31/437 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01);
Abstract

The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.


Find Patent Forward Citations

Loading…